✦ LIBER ✦

Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin’s lymphoma

✍ Scribed by Yair Herishanu; Chava Perry; Rony Braunstein; Ur Metser; Odelia Goor; Ori Rogowski; Shlomo Berliner; Aaron Polliack; Elizabeth Naparstek

Book ID: 114794225
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 465 KB
Volume: 79
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.2007.00894.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

C-Reactive Protein Serum Level is a Valu

C-Reactive Protein Serum Level is a Valuable and Simple Prognostic Marker in Non Hodgkin's Lymphoma

✍ Legouffe, E. ;Rodriguez, C. ;Picgt, M. C. ;Richard, B. ;Klein, B. ;Rossi, J. F. 📂 Article 📅 1998 🏛 Informa plc 🌐 English ⚖ 534 KB

CEOP treatment results and validity of t

CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma

✍ C. S. Chim; Y. L. Kwong; A. K. W. Lie; C. K. Lee; R. Liang 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 2 views

From 1991 to 1997, we have treated 78 newly diagnosed patients with aggressive non-Hodgkin's lymphoma with a modified CHOP regimen in which epirubicin (60 mg/m 2 ) was used in place of doxorubicin (50 mg/m 2 ), i.e. CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone). The median age wa